HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rafael Delgado Selected Research

DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)

10/2021Low-Valent Calix[4]arene Glycoconjugates Based on Hydroxamic Acid Bearing Linkers as Potent Inhibitors in a Model of Ebola Virus Cis-Infection and HCMV-gB-Recombinant Glycoprotein Interaction with MDDC Cells by Blocking DC-SIGN.
6/2019Correction to Unprecedented Thiacalixarene Fucoclusters as Strong Inhibitors of Ebola cis-Cell Infection and HCMV-gB Glycoprotein/DC-SIGN C-type Lectin Interaction.
1/2019Unprecedented Thiacalixarene Fucoclusters as Strong Inhibitors of Ebola cis-Cell Infection and HCMV-gB Glycoprotein/DC-SIGN C-type Lectin Interaction.
1/2019Synthesis of Highly Efficient Multivalent Disaccharide/[60]Fullerene Nanoballs for Emergent Viruses.
1/2018Nanocarbon-Based Glycoconjugates as Multivalent Inhibitors of Ebola Virus Infection.
8/2017Antiviral activity of self-assembled glycodendro[60]fullerene monoadducts.
2/2013Glycofullerenes inhibit viral infection.
7/2011Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection.
7/20071,2-Mannobioside mimic: synthesis, DC-SIGN interaction by NMR and docking, and antiviral activity.
1/2005Role of the C-type lectins DC-SIGN and L-SIGN in Leishmania interaction with host phagocytes.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rafael Delgado Research Topics

Disease

28Infections
01/2022 - 01/2002
7COVID-19
02/2022 - 01/2020
7Ebola Hemorrhagic Fever
01/2021 - 07/2002
5Virus Diseases (Viral Diseases)
01/2019 - 07/2007
4Viremia
12/2020 - 11/2005
2Coinfection
07/2021 - 02/2012
1African Swine Fever
01/2022
1Drug-Related Side Effects and Adverse Reactions
01/2022
1Lymphoma (Lymphomas)
11/2021
1B-Cell Lymphoma (Lymphoma, B Cell)
11/2021
1HIV Infections (HIV Infection)
02/2013
1Melanoma (Melanoma, Malignant)
02/2009
1Neoplasm Metastasis (Metastasis)
02/2009
1Neoplasms (Cancer)
02/2009
1Chronic Disease (Chronic Diseases)
12/2007
1Cutaneous Leishmaniasis
01/2005
1Leishmaniasis
01/2005
1Ulcer
03/2002

Drug/Important Bio-Agent (IBA)

14DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA
10/2021 - 07/2002
8Proteins (Proteins, Gene)FDA Link
01/2022 - 07/2007
8Glycoproteins (Glycoprotein)IBA
10/2021 - 07/2007
5LigandsIBA
01/2019 - 07/2007
4VaccinesIBA
02/2022 - 01/2005
4GlycoconjugatesIBA
10/2021 - 02/2013
4Antiviral Agents (Antivirals)IBA
01/2021 - 07/2007
4C-Type Lectins (C-Type Lectin)IBA
06/2019 - 01/2005
4Biological ProductsIBA
01/2019 - 07/2010
4CarbohydratesIBA
01/2018 - 07/2007
3DNA (Deoxyribonucleic Acid)IBA
12/2020 - 03/2002
3LopinavirFDA Link
01/2011 - 11/2006
3Ritonavir (Norvir)FDA Link
01/2011 - 11/2006
2Polysaccharides (Glycans)IBA
01/2019 - 01/2012
2LectinsIBA
02/2013 - 07/2011
2Dendrimers (Dendrons)IBA
07/2011 - 09/2004
1Nucleic AcidsIBA
01/2022
1Prednisone (Sone)FDA LinkGeneric
11/2021
1Rituximab (Mabthera)FDA Link
11/2021
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2021
1Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021
1Etoposide (VP 16)FDA LinkGeneric
11/2021
1Vincristine (Oncovin)FDA LinkGeneric
11/2021
1CholesterolIBA
11/2021
1AcidsIBA
10/2021
1Hydroxamic Acids (Hydroxamic Acid)IBA
10/2021
1calix(4)areneIBA
10/2021
1Calixarenes (Calixarene)IBA
10/2021
1ProcalcitoninIBA
07/2021
1Neutralizing AntibodiesIBA
06/2021
1SARS-CoV-2 spike proteinIBA
01/2021
1CytokinesIBA
01/2021
1MVA vaccineIBA
01/2021
1MaravirocFDA Link
12/2020
1Immunoglobulin G (IgG)IBA
01/2020
1Anti-Bacterial Agents (Antibiotics)IBA
01/2019
1MucinsIBA
11/2018
1ElectrolytesIBA
01/2018
1CarbonIBA
01/2017
1Alkynes (Acetylenes)IBA
01/2017
1SugarsIBA
01/2017
1FullerenesIBA
01/2017
1AntibodiesIBA
02/2016
1Pharmaceutical PreparationsIBA
02/2012
1PolyestersIBA
07/2011
1Protease Inhibitors (Protease Inhibitor)IBA
01/2011
1dihydroceramide desaturaseIBA
07/2010
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
02/2009
1Chemokine ReceptorsIBA
02/2009
1Metalloproteases (Metalloproteinases)IBA
02/2009
1DisaccharidesIBA
07/2007
1FilaminsIBA
07/2007
1RNA (Ribonucleic Acid)IBA
11/2005
1Mannose (D-Mannose)IBA
09/2004
1cyanovirin NIBA
04/2004
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
04/2004
1BH30sucManIBA
12/2003
1Coloring Agents (Dyes)IBA
03/2002
1SYBR Green IIBA
03/2002
1Hexadimethrine BromideIBA
01/2002

Therapy/Procedure

10Therapeutics
01/2022 - 11/2006
1Radiotherapy
11/2021
1Drug Therapy (Chemotherapy)
11/2020
1Highly Active Antiretroviral Therapy (HAART)
11/2005